The Food and Drug Administration (FDA) announces it has taken an additional step in harnessing real-world data to help inform the agency’s overall response to the COVID-19 public health emergency. The FDA is announcing its participation in the COVID-19 Diagnostics Evidence Accelerator, a multi-stakeholder collaborative project to advance the development of diagnostics. The Diagnostics Evidence Accelerator is organized by the Reagan-Udall Foundation for the FDA in collaboration with Friends of Cancer Research.
“While there are current studies of viral diagnostic and antibody tests using traditional assessment methods, the Diagnostics Evidence Accelerator will allow the community to analyze both diagnostic and clinical data in real time, which has the potential to contribute to the scientific evaluation of diagnostic tools and medical interventions for COVID-19,” said Amy Abernethy, MD, PhD, the FDA's principal deputy commissioner. “FDA’s participation in the Diagnostics Evidence Accelerator is another example of how we are working with a broad set of experts in healthcare data and analytics to understand the performance of SARS-CoV-2 tests and to inform clinical and public health decision-making.”
The Diagnostics Evidence Accelerator is the companion project to the previously announced Therapeutic Evidence AcceleratorExternal Link Disclaimer, which brings together leading experts in health data aggregation and analytics in a unified, collaborative effort to share insights, compare results and answer key questions to inform the collective COVID-19 response.
“This collaboration with the FDA, scientists and data experts is meeting the urgency of the moment to speed the pace of diagnostic testing,” said Ellen V. Sigal, chair of both the Reagan-Udall Foundation and Friends of Cancer Research. “We all share the goal of deepening our understanding of COVID-19 on every front to ensure that patients receive the best care as quickly and safely as possible.”
Key research questions that will be examined through the Diagnostics Evidence Accelerator include evaluating the real-world performance of SARS-CoV-2 diagnostic tests and antibody tests, how they are best used to tailor testing strategies to specific populations, and what test results and data may reveal about the prevalence of disease, chains of transmission, and individual and population-level immunity. This effort will focus on the use of real-world data to understand whether the presence of antibodies can indicate future immunity and if so, which specific antibodies and epitopes contribute to some level of protection against future infection.
Using real-world data can also provide actionable information about the prevalence of SARS-CoV-2 in specific populations and highlight individual risk factors for patients, helping to improve our understanding of the disease, tailor public health interventions and strategies to mitigate risks for individuals and communities, and help stop the spread of SARS-CoV-2. The evidence generated through the Diagnostics Accelerator is intended to be complementary to other studies that have been conducted or are underway as well as to address questions not yet answered.
“We recognize that questions related to the accuracy of diagnostic tests require different data elements that are not as widely available as those in the therapeutic space. They also require a different approach to data integration and analysis,” said Jeff Shuren, MD, JD, director of FDA's Center for Devices and Radiological Health. “The aim of the Accelerator is to propose questions, refine them, evaluate the feasibility of different approaches, and bring together groups that have the data to answer the questions and develop lasting solutions. Ultimately, we hope that real-world data can provide a more generalizable and rapid read-out of results than traditional clinical trials.”
The Diagnostics Evidence Accelerator represents the type of data-focused effort that has the potential to inform our future emergency efforts. In an emergency setting, the FDA may issue emergency use authorizations (EUAs) which are evaluated using a different standard than is required for approval or clearance in non-emergency situations. Gaining a better understanding of the real-world performance characteristics of diagnostic tests and antibody tests can help inform future EUAs.
Source FDA
Thanks for a marvelous posting! I truly enjoyed reading it, you could be a great author. I will make sure to bookmark your blog and will come back in the future. I want to encourage that you continue your great writing, have a nice weekend!
Wow, amazing blog layout! How long have you been blogging for? you make blogging look easy. The overall look of your web site is great, let alone the content!
I’m impressed, I must say. Rarely do I encounter a blog that’s equally educative and interesting, and let me tell you, you have hit the nail on the head. The issue is something which not enough people are speaking intelligently about. I’m very happy that I stumbled across this in my search for something concerning this.
Pretty section of content. I just stumbled upon your website and in accession capital to assert that I acquire in fact enjoyed account your blog posts. Any way I’ll be subscribing to your augment and even I achievement you access consistently fast.
Pretty! This was an extremely wonderful post. Thanks for providing this information.
Hi there to every one, it’s in fact a pleasant for me to pay a visit this website, it contains precious Information.
Aw, this was a very nice post. Spending some time and actual effort to create a great article but what can I say I procrastinate a lot and never seem to get anything done.
Hi, I do believe this is an excellent web site. I stumbledupon it 😉 I’m going to come back once again since I book-marked it. Money and freedom is the best way to change, may you be rich and continue to help other people.
This article will help the internet users for building up new blog or even a blog from start to end.
Howdy! Someone in my Myspace group shared this site with us so I came to look it over. I’m definitely enjoying the information. I’m book-marking and will be tweeting this to my followers! Terrific blog and terrific design and style.
Terrific article! This is the type of information that are supposed to be shared around the web. Disgrace on the seek engines for now not positioning this submit upper! Come on over and visit my site . Thank you =)